236 related articles for article (PubMed ID: 11249504)
1. Current management of acromegaly.
Díez JJ; Iglesias P
Expert Opin Pharmacother; 2000 Jul; 1(5):991-1006. PubMed ID: 11249504
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological management of acromegaly: a current perspective.
Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
[TBL] [Abstract][Full Text] [Related]
3. Cabergoline in acromegaly.
Kuhn E; Chanson P
Pituitary; 2017 Feb; 20(1):121-128. PubMed ID: 28025719
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
Öberg K; Lamberts SW
Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
[TBL] [Abstract][Full Text] [Related]
5. Current status and future directions of pharmacological therapy for acromegaly.
Mercado M; Espinosa E; Ramírez C
Minerva Endocrinol; 2016 Sep; 41(3):351-65. PubMed ID: 26485036
[TBL] [Abstract][Full Text] [Related]
6. Management of endocrine disease: GH excess: diagnosis and medical therapy.
Andersen M
Eur J Endocrinol; 2014 Jan; 170(1):R31-41. PubMed ID: 24144967
[TBL] [Abstract][Full Text] [Related]
7. Current and future medical treatments for patients with acromegaly.
Maffezzoni F; Formenti AM; Mazziotti G; Frara S; Giustina A
Expert Opin Pharmacother; 2016 Aug; 17(12):1631-42. PubMed ID: 27352098
[TBL] [Abstract][Full Text] [Related]
8. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.
Colao A; Auriemma RS; Pivonello R
Pituitary; 2016 Apr; 19(2):210-21. PubMed ID: 26290466
[TBL] [Abstract][Full Text] [Related]
9. LIMITATIONS OF CURRENT APPROACHES FOR THE TREATMENT OF ACROMEGALY.
Shanik MH
Endocr Pract; 2016 Feb; 22(2):210-9. PubMed ID: 26437214
[TBL] [Abstract][Full Text] [Related]
10. Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly.
Arihara Z; Sakurai K; Yamashita R; Niitsuma S; Ueno T; Yamamura N; Yamada S; Inoshita N; Takahashi K
Tohoku J Exp Med; 2014 Oct; 234(2):129-35. PubMed ID: 25253414
[TBL] [Abstract][Full Text] [Related]
11. Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.
Bacigaluppi S; Gatto F; Anania P; Bragazzi NL; Rossi DC; Benvegnu G; Nazzari E; Spaziante R; Giusti M; Ferone D; Zona G
Endocrine; 2016 Mar; 51(3):524-33. PubMed ID: 25982150
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of acromegaly].
Dénes J; Korbonits M; Hubina E; Góth M
Orv Hetil; 2010 Aug; 151(34):1384-93. PubMed ID: 20705553
[TBL] [Abstract][Full Text] [Related]
13. Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists.
Howlett TA; Willis D; Walker G; Wass JA; Trainer PJ;
Clin Endocrinol (Oxf); 2013 Nov; 79(5):689-99. PubMed ID: 23574573
[TBL] [Abstract][Full Text] [Related]
14. [Optimization of the medical treatment for acromegaly].
Díez JJ; Iglesias P
Med Clin (Barc); 2013 Apr; 140(8):360-5. PubMed ID: 23103101
[TBL] [Abstract][Full Text] [Related]
15. 60 YEARS OF NEUROENDOCRINOLOGY: Acromegaly.
Capatina C; Wass JA
J Endocrinol; 2015 Aug; 226(2):T141-60. PubMed ID: 26136383
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness analysis of octreotide long acting release and lanreotide slow release for the treatment of postoperative patients with active acromegaly in China].
Xuan JW; Zhang ZY; Wang YF; Mao ZG; Lu YJ; Wang RZ
Zhonghua Yi Xue Za Zhi; 2017 Mar; 97(10):765-769. PubMed ID: 28316158
[No Abstract] [Full Text] [Related]
17. Medical therapy in acromegaly.
Sherlock M; Woods C; Sheppard MC
Nat Rev Endocrinol; 2011 May; 7(5):291-300. PubMed ID: 21448141
[TBL] [Abstract][Full Text] [Related]
18. Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women.
Caron P; Broussaud S; Bertherat J; Borson-Chazot F; Brue T; Cortet-Rudelli C; Chanson P
J Clin Endocrinol Metab; 2010 Oct; 95(10):4680-7. PubMed ID: 20660047
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
Suda K; Inoshita N; Iguchi G; Fukuoka H; Takahashi M; Nishizawa H; Yamamoto M; Yamada S; Takahashi Y
Endocr J; 2013; 60(4):507-15. PubMed ID: 23291436
[TBL] [Abstract][Full Text] [Related]
20. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly.
Mattar P; Alves Martins MR; Abucham J
Neuroendocrinology; 2010; 92(2):120-7. PubMed ID: 20802256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
